IBA Inc

Millbury, MA, United States
Millbury, MA, United States
SEARCH FILTERS
Time filter
Source Type

News Article | May 18, 2017
Site: www.prweb.com

Irving Burton Associates (IBA), a leading technology consulting services firm, is pleased to announce that it has been appraised at Level 3 of the CMMI Institute’s Capability Maturity Model Integration (CMMI)® for both Development and Services. The appraisal was performed independently by Acuity Inc. CMMI® is a capability improvement approach that boast decades of successful results. This proven methodology provides organizations with the essential elements of effective processes that ultimately improve their performance. “This appraisal is exemplary of IBA’s commitment to the success of our federal clients” said Karthik Srinivasan, Senior Vice President at IBA. “A successful Maturity Level 3 appraisal confirms our organization-wide dedication to providing reliable, predictable processes that deliver innovative solutions and services on time and within budget. The team at IBA has always been passionate about delivering solutions and services that meet and exceed industry standards – this appraisal is an excellent affirmation of our continuing efforts.” An appraisal at Maturity Level 3 indicates that IBA is performing at a “defined” level. At this level, processes are well characterized and understood, and are described in standards, procedures, tools, and methods. The organization’s set of standard processes, which is the basis for Maturity Level 3, is established and continues to improve over time. About CMMI The CMMI® Institute, a subsidiary of Carnegie Mellon University, is dedicated to elevating organizational performance through best-in-class solutions to real-world challenges. The Institute is the home of the Capability Maturity Model Integration (CMMI)® for Development, Services, and Acquisition; the People Capability Maturity Model; and the Data Management Maturity Model (DMM)SM, which are capability improvement models that create high-performance, high-maturity cultures. The models are used in thousands of organizations worldwide to deliver business results that serve as differentiators in the global market. About IBA IBA is a woman-owned service provider headquartered in Falls Church, VA, with regional offices in San Antonio, TX, Frederick, MD, and Washington, DC. This leading technology consulting services firm has over 37 years of experience delivering innovative work on the nation’s largest business and Health IT projects. IBA’s teams specialize in Agile development, Agile transformation, Enterprise IT, Mobile apps, program management and financial services. To learn more about IBA’s capabilities, please visit http://www.ibacorp.us.


News Article | July 14, 2017
Site: globenewswire.com

Louvain-la-Neuve, Belgium, July 14, 2017, 5.40 p.m. - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on 13 July 2017. About IBA IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com For further information, please contact:


News Article | July 13, 2017
Site: globenewswire.com

Louvain-la-Neuve, Belgium, July 11, 2017, 5.40 p.m. - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on 11 July 2017. About IBA IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com For further information, please contact:


AMSTERDAM and SINGAPORE, July 12, 2017 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and the Singapore Institute of Advanced Medicine Holdings (SAM) today announced a collaboration with Varian Medical Systems and IBA Worldwide to build the new Advanced Medicine Oncology Centre based at Biopolis, the international biomedical research hub in Singapore. The oncology center will provide world-class imaging, treatment delivery and clinical informatics technologies with the intent to comprehensively address the region's fast-growing number of people confronted with cancer. SAM is driving the collaboration by investing up to SGD 100 million (approximately USD 72 million) towards the development of a center of excellence for oncology in the Southeast Asia region. The new research, training and treatment center will provide cutting-edge oncology solutions for use by healthcare professionals and researchers. Projected to open in stages from 2018 onwards, the center will also aim to provide a platform for professional training to meet the evolving needs of the healthcare industry. Through research, clinical trials and development of leading cancer treatment therapies, the Advanced Medicine Oncology Centre will house new innovations and treatment protocols developed via a multi-disciplinary approach for better and more personalized patient care, potentially improved outcomes and a better on-going quality of life for patients. "The new Advanced Medicine Oncology Centre aligns with the founding goal of the Singapore Institute of Advanced Medicine Holdings to provide earlier detection and first-time-right diagnosis of cancer as well as safer, more cost effective treatment by advancing care enabled through research, technology and education," said Dr. Djeng Shih Kien, Founder and Chairman, Singapore Institute of Advanced Medicine Holdings. "I am proud to be leading this milestone with our partners, marking a step forward in the treatment of cancer, which affects much of humanity." The Advanced Medicine Oncology Centre will house a range of Philips' advanced diagnostic imaging systems and clinical informatics. In addition to Philips' Ingenia MR and IQon spectral CT systems, the center will have two of Philips' Vereos PET/CT scanners[1], the world's first and only fully digital PET/CT systems. Vereos uses Philips' proprietary Digital Photon Counting (DPC) technology resulting in improved detectability and characterization of small lesions[2]. It offers uncompromised lesion detectability and quantification at half the PET dose[3], together with overall sensitivity gains compared to analog[4] systems. Varian's ProBeam® Compact system will provide high-quality proton therapy. The ProBeam® is the only single room system capable of fully rotational intensity modulated proton therapy (IMPT). IBA's Cyclone Kiube technology will enable complete on-site production and utilization of PET radiopharmaceuticals and tracers for lesion visualization using Philips digital PET/CT. This will help the oncology center to deliver new treatments with a unique combination of speed, flexibility and cost efficiency. The center will use Philips IntelliSpace Portal 9.0 for advanced visual analysis and quantification of medical images helping clinicians to assess and quickly diagnose conditions using clinical applications that are optimized for patient evaluation throughout the treatment process. "Cancer affects people from all walks of life and is among the leading causes of death worldwide, accounting for more than 4 million deaths in Asia in 2016[5]," said Diederik Zeven, General Manager, Health Systems, Philips ASEAN Pacific. "Philips is enabling the advancement of medical research through our deep heritage in healthcare innovation and collaboration with medical partners. The new Advanced Medicine Oncology Centre is well-positioned to spearhead cancer research and treatment in Singapore and the region and we are very proud to be a strategic partner." "This center will be the first installation of Varian's ProBeam Compact proton therapy system, which is designed to enable space-constrained sites such as this to offer state-of-the-art technology for cancer patients," said Dr. Moataz Karmalawy, General Manager of Varian's Particle Therapy division. "This center will open up additional opportunities for both education and research. Singapore is joining an exclusive group of countries that have facilities like these to advance our understanding of not only proton therapy, but also immunotherapy and other cell-based treatments." Besides cancer, age-related health diseases are a growing concern with Asia-Pacific projected to comprise two thirds of the world's elderly by 2050[6]. In the longer term, the center will also manage a number of diagnostic and therapeutic medical specialties by housing world-class imaging solutions to address cardiovascular and neurological disorders such as stroke and Alzheimer's disease. For further information, please contact: Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 70,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscentre. About Singapore Institute of Advanced Medicine Holdings Pte. Ltd. Singapore Institute of Advanced Medicine Holdings Pte. Ltd. is the latest venture by Dr. S.K. Djeng and his associates, who have a record of success in making cutting edge healthcare technology available in Singapore. Their vision is to use technology for patient care, and provide comprehensive diagnostic and therapeutic services including laboratory medicine, imaging and proton therapy. More information can be found at www.advancedmedicine.sg Varian Medical Systems focuses energy on saving lives and is the world's leading manufacturer of medical devices and software for treating and managing cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,400 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter. IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company. Based on longstanding expertise, IBA RadioPharma Solutions supports hospitals and radiopharmaceutical distribution centers with their in-house radioisotopes production by providing them global solutions, from project design to the operation of their facility. In addition to high-quality technology production equipment (cyclotron solutions, targetry systems, synthesizers, control systems), IBA has developed in-depth experience in setting up GMP radiopharmaceuticals production centers. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com [1] Philips' Vereos is approved by U.S. Food and Drug Administration. The application and availability of Philips' Vereos PET/CT scanners outside of the United States is subject to approval of individual country's regulatory authority [2] Nguyen NC, Image Quality and Diagnostic Performance of a Digital PET Prototype in Patients with Oncologic Diseases: Initial Experience and Comparison with Analog PET, J Nucl Med 2015; 56:1378–1385 [3] Liu X et al, Impact of FDG Dose Reduction on Lesion Quantification in Dynamic PET: A Simulation Study Based on Clinical Trial Data, SNMMI 2016 [6] United Nations Economic and Social Commission for Asia and the Pacific (ESCAP), Ageing: Overview


News Article | July 11, 2017
Site: globenewswire.com

Louvain-la-Neuve, Belgium, July 10, 2017, 5.40 p.m. - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notifications received on 7 July 2017*. About IBA IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com For further information, please contact:


News Article | June 15, 2017
Site: www.prnewswire.com

IBA Group - http://www.ibagroupit.com - se voit inclus dans la catégorie des « Leaders » et est reconnu comme « Super étoile » du Global Outsourcing 100 pour son excellence soutenue et comme Meilleure compagnie (« étoile ») en termes de références clientèle, prix et certifications, programmes pour l'innovation et programmes pour la responsabilité sociétale des entreprises. Actuellement dans sa 11e année, le Global Outsourcing 100 reconnaît les meilleurs prestataires de services d'externalisation au monde. Les entreprises sont d'abord organisées en fonction des critères « Leader » ou « Étoile montante », puis évaluées à l'aune des cinq catégories de jugement suivantes : taille et croissance, références client, prix et certifications, programmes pour l'innovation et responsabilité sociétale des entreprises (RSE). « Les acheteurs comprennent qu'il y a des centaines de prestataires de services et de consultants qualifiés sur le marché, mais ce qu'ils doivent véritablement comprendre désormais est ce qui fait de chacun une entité exceptionnelle », a déclaré la PDG d'IAOP, Debi Hamill. « C'est précisément ce que viennent de faire les listes du Global Outsourcing 100 et des Meilleurs consultants au monde. Nous sommes heureux de reconnaître IBA Group parmi les entreprises aux plus hauts scores en termes de références clientèle, prix d'entreprise et certifications, programmes pour l'innovation et RSE, et comme « super étoile » de Global Outsourcing 100 en termes d'excellence soutenue. Sergei Levteev, président d'IBA Group, a ajouté : « IBA Group a été catalogué sur la liste des entreprises du Global Outsourcing 100 dans la catégorie 'Leader' pour la cinquième année consécutive. Nous avons démontré sans relâche notre engagement à l'égard des plus hautes normes d'excellence, de service à la clientèle, d'innovation et de responsabilité sociétale des entreprises. Le Global Outsourcing 100 donne une vision complète de la façon dont une entreprise se comporte par rapport à ses homologues du secteur. Cette année, IBA Group n'a pas seulement confirmé ses quatre 'étoiles' de l'année dernière, mais a également reçu une récompense de « Super étoile » de la part du Global Outsourcing 100 pour l'excellence soutenue. Je crois que cela est assez éloquent. Cependant, ce n'est le moment de nous reposer sur nos lauriers. Nous allons continuer à travailler, à nous développer et lutter au nom de nouveaux objectifs et de nouveaux exploits. »


News Article | June 15, 2017
Site: www.prnewswire.com

IBA Group (http://www.ibagroupit.com) wird in der Kategorie "Leaders" aufgeführt und als Super Star of the Global Outsourcing 100 for Sustained Excellence und als Top Company (‚Star') für Kundenreferenzen, Preise & Zertifizierungen, Innovationsprogramme sowie Programme für soziale unternehmerische Verantwortung gewürdigt. Die Summe der Punktezahl in diesen Kategorien entscheidet über die Aufnahme in die Liste. Sämtliche Unternehmen auf der Liste haben sich weltweit besonders verdient gemacht. ‚Stars' bekommen alle Unternehmen, die sich in einer oder mehr Bewertungskategorien hervorgetan haben. Sergei Levteev, Vorsitzender der IBA Group, fügte hinzu: "IBA Group hat es im fünften Jahr in Folge in der Kategorie ‚Leader' in die Liste ‚Global Outsourcing 100' geschafft.  Wir haben wiederholt unser Bemühen um die höchsten Standards bei Leistung, Kundenservice, Innovation und sozialer Verantwortung unter Beweis gestellt. Die Liste ‚Global Outsourcing 100' bietet einen konsistenten Vergleich, wie ein Unternehmen gegenüber anderen Branchenteilnehmern abschneidet. Dieses Jahr hat IBA Group nicht nur seine vier ‚Stars' vom letzten Jahr verteidigt, sondern auch den Preis als Superstar der Global Outsourcing 100 für nachhaltige Spitzenleistung erhalten. Ich glaube, das ist selbstredend. Wir ruhen uns aber auf diesem Erfolg nicht aus. Wir werden weiter arbeiten, entwickeln und uns neue Ziele und Maßstäbe setzen."


News Article | June 15, 2017
Site: www.prnewswire.co.uk

IBA Group - http://www.ibagroupit.com - is included in the Leaders category and recognized as a Super Star of the Global Outsourcing 100 for Sustained Excellence and as a Top Company ('star') for Customer References, Awards & Certifications, Programs for Innovation, and Programs for Corporate Social Responsibility. Now in its 11th year, The Global Outsourcing 100 recognizes the world's best outsourcing service providers. Companies are first organized by Leader or Rising Star criteria and then evaluated based on the following five judging categories: Size and Growth, Customer References, Awards and Certifications, Programs for Innovation, and Corporate Social Responsibility (CSR). The aggregate scores from the areas above determine inclusion on the list. All companies included on the list have demonstrated their global excellence; 'stars' are awarded to all companies distinguishing themselves in one or more judging category. "Buyers understand there are hundreds of qualified service providers and advisors out there, but what they really need to understand now is what makes each one exceptional," said IAOP CEO, Debi Hamill. "The Global Outsourcing 100 and World's Best Advisors lists have done just that. We are proud to recognize IBA Group for being among the highest rated companies in customer references, company awards and certifications, programs for innovation, and CSR, and as a super star of the Global Outsourcing 100 for Sustained Excellence." Sergei Levteev, IBA Group Chairman, added: "IBA Group has been listed among The Global Outsourcing 100 companies in the Leader category for the fifth consecutive year.  We have repeatedly demonstrated commitment to the highest standards of excellence, customer service, innovation, and social responsibility. The Global Outsourcing 100 gives a consistent view of how a company is performing against industry peers. This year, IBA Group has not only confirmed its four 'stars' from last year, but was also awarded a Super Star of the Global Outsourcing 100 for Sustained Excellence. I believe it speaks for itself. However, it is not the time to rest on the laurels. We will keep working, developing, and striving for new goals and heights." See the 2017 Global Outsourcing 100 list at


News Article | May 10, 2017
Site: globenewswire.com

Louvain-La-Neuve, Belgium, May 10, 2017 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today provides a trading update for the first quarter ending 31 March 2017. Olivier Legrain, Chief Executive Officer of IBA, commented: "We are pleased to have made good progress in this first quarter of 2017 and are on track to meet our growth targets. Dosimetry has seen a good recovery across all regions and is now positively contributing to our REBIT. Our production expansion and regionalization strategy to meet growing global demand continues to be rolled out and we are currently installing eight projects across the globe and getting ready to install another 17 internationally. "In Proton Therapy, however, several recent delays in project execution caused by customer building delays lead us to slightly adjust our full year guidance for 2017. While our guidance on revenue growth remains unchanged at around 15% to 20%, the project execution delays impact our revenue recognition and, to some extent, our operational leverage. Due to this, we revise our guidance on REBIT to between 10% and 12% for 2017, and around 13% for 2018. "We are confident in the strong prospects for IBA in 2017 and beyond due to our growth strategy, the significant market potential in proton therapy and our focus on maintaining the world's leading proton therapy offering." IBA reported the following segmental trends and news during the first quarter of 2017: Proton therapy's penetration of the radiation therapy market continues to grow due to increasing interest from the clinical community, affordability and technological advances. To keep ahead of and to lead this growth, IBA continues to scale up production capacity, including investment in a new superconducting synchrocyclotron assembly line (for Proteus®ONE*), and a new customer center, with an expected further combined CAPEX of about EUR 16 million, of which around EUR 10 million will be invested in 2017. The Company is also recruiting an additional 200 engineers and qualified staff, worldwide, through 2017. IBA has a high backlog of EUR 316 million and the sustainable revenue source from service and maintenance contracts now represents EUR 673 million of revenue over the next 10-15 years. IBA expects to achieve revenue growth of between 15% to 20% in 2017 and double digit thereafter. The Company expects its operating margin to be 10% to 12% in 2017, increasing to around 13% by 2018 and stabilizing at around 15% by 2020. IBA is planning to maintain a dividend payout ratio of 30%. This guidance is not only based upon the continued expected growth of the proton therapy market but also the balance between the economies of scale that we can achieve at a higher production rate. In addition, the growing importance of service revenue versus the increased demand driven by the equipment price tag reduction in the proton therapy market and our continued investment in R&D and software capabilities are anticipated to be contributing factors. In accordance with the Royal Decree of 14 November 2007, IBA indicates that this Trading Update has been prepared by the Chief Executive Officer (CEO) and the Chief Financial Officer (CFO). About IBA IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com *Proteus®ONE and Proteus®PLUS are brand names of Proteus 235 For further information, please contact:


News Article | June 15, 2017
Site: www.prnewswire.com

IBA Group - http://www.ibagroupit.com - is included in the Leaders category and recognized as a Super Star of the Global Outsourcing 100 for Sustained Excellence and as a Top Company ('star') for Customer References, Awards & Certifications, Programs for Innovation, and Programs for Corporate Social Responsibility. Now in its 11th year, The Global Outsourcing 100 recognizes the world's best outsourcing service providers. Companies are first organized by Leader or Rising Star criteria and then evaluated based on the following five judging categories: Size and Growth, Customer References, Awards and Certifications, Programs for Innovation, and Corporate Social Responsibility (CSR). The aggregate scores from the areas above determine inclusion on the list. All companies included on the list have demonstrated their global excellence; 'stars' are awarded to all companies distinguishing themselves in one or more judging category. "Buyers understand there are hundreds of qualified service providers and advisors out there, but what they really need to understand now is what makes each one exceptional," said IAOP CEO, Debi Hamill. "The Global Outsourcing 100 and World's Best Advisors lists have done just that. We are proud to recognize IBA Group for being among the highest rated companies in customer references, company awards and certifications, programs for innovation, and CSR, and as a super star of the Global Outsourcing 100 for Sustained Excellence." Sergei Levteev, IBA Group Chairman, added: "IBA Group has been listed among The Global Outsourcing 100 companies in the Leader category for the fifth consecutive year.  We have repeatedly demonstrated commitment to the highest standards of excellence, customer service, innovation, and social responsibility. The Global Outsourcing 100 gives a consistent view of how a company is performing against industry peers. This year, IBA Group has not only confirmed its four 'stars' from last year, but was also awarded a Super Star of the Global Outsourcing 100 for Sustained Excellence. I believe it speaks for itself. However, it is not the time to rest on the laurels. We will keep working, developing, and striving for new goals and heights." See the 2017 Global Outsourcing 100 list at

Loading IBA Inc collaborators
Loading IBA Inc collaborators